Good evening :)
$
₹
Qiagen NV

Qiagen NV

QGEN

NYSE
Asset Logo

Qiagen NV

QGEN

NYSE
$50.810.03% (-0.01)
$
₹
$50.810.03% (-0.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $10.4B the stock is ranked 944

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

25.57
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.09
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$1.97
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.34
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

19.49%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.72%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 12 analysts reports

Buy
1 analyst
Hold
11 analysts
Sell
0 analyst

Price Upside

-3.56%

Earnings Growth

-1.36%

Rev. Growth

+2.18%

See Detailed Forecast

Company Profile

Company Profile

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
36.83
36.83
1Y Return
24.93%
24.93%
Buy Reco %
85.18
85.18
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
34.60
34.60
1Y Return
20.11%
20.11%
Buy Reco %
68.18
68.18
Waters Corporation
WAT
Waters Corporation
P/E Ratio
116.43
116.43
1Y Return
27.29%
27.29%
Buy Reco %
78.26
78.26
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
31.94
31.94
1Y Return
25.04%
25.04%
Buy Reco %
90.00
90.00
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
41.00
41.00
1Y Return
103.84%
103.84%
Buy Reco %
47.61
47.61
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -3.56% growth, versus a trailing 3-year CAGR of 11.64%.

2026
Current$50.83Baseline
Analyst Target - 1 year
Target$49.02-3.56%

All values in $

202220232024202520262027$41.47$46.28$51.10Target-3.56%
2026
Current$50.83Baseline
Analyst Target - 1 year
Target$49.02-3.56%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 2.18% growth, versus a trailing 3-year CAGR of -0.81%.

2025
Current$2.08Baseline
Forecast for Dec 2026
High$2.15+3.32%
Average$2.13+2.18%
Low$2.12+1.48%

All values in $ Billion

2021202220232024202520262.252.141.961.972.08Low+1.48%Average+2.18%High+3.32%
2025
Current$2.08Baseline
Forecast for Dec 2026
High$2.15+3.32%
Average$2.13+2.18%
Low$2.12+1.48%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -1.36% growth, versus a trailing 3-year CAGR of -2.19%.

2025
Current$2.47Baseline
Forecast for Dec 2026
High$2.47+0%
Average$2.44-1.36%
Low$2.42-1.9%

All values in $

2021202220232024202520262.972.642.32.362.47Low-1.9%Average-1.36%High-0%
2025
Current$2.47Baseline
Forecast for Dec 2026
High$2.47+0%
Average$2.44-1.36%
Low$2.42-1.9%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

532.5
130
540.4
107.8
492.3
68
535
103.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue458.79496.34501.86521.20483.45533.54532.58540.42492.32535.04
Net Income80.67-183.4698.0588.3290.7596.25130.04107.8268.04103.40
Net Profit Margin17.58%-36.96%19.53%16.94%18.77%18.03%24.41%19.95%13.82%19.32%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Qiagen NV 25.573.091.34
Thermo Fisher Scientific Inc36.834.611.99
Agilent Technologies Inc34.606.581.45
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare QGEN with any stock or ETF
Compare QGEN with any stock or ETF
Comparing from
QGEN
TMO
A
Loading...

Frequently asked questions

  1. Qiagen NV (QGEN) share price today is $50.81 as of November 5, 2026 at 8:26 PM IST. The stock touched a day high of $50.81 and a day low of $50.68.

  2. Qiagen NV stock trades on NYSE under the ticker symbol QGEN.

  3. Qiagen NV's market capitalization is $10.4B as of November 5, 2026 at 8:26 PM IST.

  4. Qiagen NV's price-to-earnings (P/E) ratio is 25.57 as of November 5, 2026.

  5. Qiagen NV's price-to-book (P/B) ratio is 3.09 as of November 5, 2026.

  6. Yes, Qiagen NV pays a dividend, with a current dividend yield of 0.72%.

  7. Yes, You can buy Qiagen NV shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Qiagen NV shares in three steps: 1. Search Qiagen NV on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Qiagen NV trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Qiagen NV (QGEN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1968 shares at the current price of $50.81.

Loading...